

Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. <b>290673US0PCT</b>		SERIAL NO. <b>10/578,183</b>	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT <b>Haruo SUGIYAMA</b>			
				FILING DATE <b>February 27, 2007</b>		GROUP <b>1645</b>	
<b>U.S. PATENT DOCUMENTS</b>							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
<b>FOREIGN PATENT DOCUMENTS</b>							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES                  NO		
	AO	03/028758	04/10/03	WIPO (w/English abstract)			
	AP	03/002142	01/09/03	WIPO (w/English abstract)			
	AQ	01/62920	08/30/01	WIPO (w/English abstract)			
	AR						
	AS						
	AT						
	AU						
	AV						
<b>OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)</b>							
	AW	KNIGHTS, Ashley John et al., "Prediction of an HLA-DR-binding peptide derived from Wilms' tumour 1 protein and demonstration of in vitro immunogenicity of WT1(124-138)-pulsed dendritic cells generated according to an optimised protocol", Cancer Immunology Immunotherapy, vol. 51, no. 5, July 2002 (2002-07) pages 271-281					
	AX	Database JP0 Proteins [Online] 17 July 2003, "Compositions and methods for WT1 specific immunotherapy", XP002473316					
	AY	Database JP0 Proteins [Online] 17 July 2003, "Cancer vaccine comprising cationic liposome and cancer antigen based on tumor suppressor gene WT1", XP002473130					
	AZ	MAY, Rena J. et al., "CD4+peptide epitopes from the WT1 oncoprotein stimulate CD4+ and CD8+T cells that recognize and kill leukemia and solid tumor cells", vol. 108, no. 11, Part 1 November 2006 (2006-11) page 1058A, XP009097422				<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							